Thomas D - Search Results

1

A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.

Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM, Estey E. Garcia-Manero G, et al. Among authors: thomas d. Haematologica. 2002 Aug;87(8):804-7. Haematologica. 2002. PMID: 12161355 Clinical Trial.

2

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Ravandi F, et al. Cancer. 2015 Dec 1;121(23):4158-64. doi: 10.1002/cncr.29646. Epub 2015 Aug 26. Cancer. 2015. PMID: 26308885 Free PMC article. Clinical Trial.

3

Central nervous system relapse in adults with acute lymphoblastic leukemia.

Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C, Faderl S, Kantarjian H. Surapaneni UR, et al. Among authors: thomas d. Cancer. 2002 Feb 1;94(3):773-9. doi: 10.1002/cncr.10265. Cancer. 2002. PMID: 11857312 Free article.

4

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.

Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S, Kantarjian H. Cortes J, et al. Among authors: thomas d. Cancer. 2002 Mar 1;94(5):1492-9. doi: 10.1002/cncr.10365. Cancer. 2002. PMID: 11920506 Free article. Clinical Trial.

5

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.

O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. O'Brien S, et al. Among authors: thomas d. Cancer. 2002 Apr 1;94(7):2024-32. doi: 10.1002/cncr.10436. Cancer. 2002. PMID: 11932905 Free article.

6

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.

Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J. Kantarjian HM, et al. Among authors: thomas d. Blood. 2003 Jan 15;101(2):473-5. doi: 10.1182/blood-2002-05-1451. Epub 2002 Sep 12. Blood. 2003. PMID: 12393385 Free article. Clinical Trial.

7

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.

Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Jeha S, Rios MB, Letvak L, Bochinski K, Arlinghaus R, Talpaz M. Kantarjian HM, et al. Among authors: thomas d. Blood. 2003 Jan 1;101(1):97-100. doi: 10.1182/blood-2002-02-0545. Epub 2002 Aug 29. Blood. 2003. PMID: 12393600 Free article. Clinical Trial.

8

Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.

Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ. Cortes J, et al. Among authors: thomas d. Cancer Chemother Pharmacol. 2002 Dec;50(6):497-500. doi: 10.1007/s00280-002-0539-y. Epub 2002 Oct 22. Cancer Chemother Pharmacol. 2002. PMID: 12451477 Clinical Trial.

9

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.

Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Alvarado Y, et al. Among authors: thomas d. Cancer Chemother Pharmacol. 2003 Jan;51(1):87-90. doi: 10.1007/s00280-002-0546-z. Epub 2002 Nov 13. Cancer Chemother Pharmacol. 2003. PMID: 12497211

10

Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.

Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H, Giles FJ. Apostolidou E, et al. Among authors: thomas d. Leuk Res. 2003 Apr;27(4):301-4. doi: 10.1016/s0145-2126(02)00171-6. Leuk Res. 2003. PMID: 12531220 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,803 results

Search Page

Filters